Soliton, Inc. (SOLY) |
| 22.58 0 (0%) 04-24 15:47 |
| Open: | 22.56 |
| High: | 22.59 |
| Low: | 22.56 |
| Volume: | 1,347,169 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 26.39 |
| Resistance 1: | 22.59 |
| Pivot price: | 22.58 |
| Support 1: | 22.57 |
| Support 2: | 22.56 |
| 52w High: | 22.6 |
| 52w Low: | 7.53 |
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas. As of December 16, 2021, Soliton, Inc. operates as a subsidiary of Allergan plc.
Financials
| EPS | -23210000.000 |
| Book Value | 0.000 |
| PEG Ratio | -0.51 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -6.00 |
| Return on Assets (ttm) | 421.4 |
| Return on Equity (ttm) | -47.6 |
Company news
Thu, 16 Dec 2021
Allergan Aesthetics Completes Acquisition of Soliton - PR Newswire
Mon, 10 May 2021
Houston medical device co. Soliton to be acquired by Allergan Aesthetics for $550M - The Business Journals
Mon, 10 May 2021
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio - PR Newswire
Wed, 05 May 2021
Introducing RESONIC™ - BioSpace
Thu, 29 Apr 2021
Soliton Receives FDA Clearance of Special 510(k) - Apr 29, 2021 - BioSpace
Tue, 09 Mar 2021
Soliton Announces Initiation of Second Animal Study for Potential RAP Treatment of Liver Fibrosis - Nasdaq
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
